Targeting malignant tumors with high precision is challenging for biomedical researchers. However, this scenario is likely to witness a paradigm shift in the near future, through the use of specially engineered bacteria, that can eliminate malignant cells efficiently.
Novartis and Versant launch Borealis with $150m funding
The new biotech company will focus on advancing renal disease treatments. Credit: PanuShot/Shutterstock. Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based
August 23, 2024